Gut microbes from schizophrenia patients trigger brain inflammation in mice

For decades, schizophrenia has been treated as a disorder of the brain alone, its hallucinations and cognitive disruptions traced to dopamine signaling, synaptic architecture, and genetic vulnerability. A new study published in Translational Psychiatry challenges that narrow framing by showing that the trillions of microbes inhabiting the human gut may actively participate in the disease process. A research team led by Ana Raquel Pereira-Santos and Sandra Morais Cardoso at the University of Coimbra demonstrates that gut bacteria from people with schizophrenia can, when transplanted into otherwise healthy mice, set off a cascade of intestinal inflammation, immune dysregulation, and brain abnormalities that mirror key features of the illness. The work provides some of the most mechanistically detailed evidence to date that the gut-immune-brain axis is not merely a bystander in schizophrenia but may be a genuine contributor to its pathology.

The rationale for the study emerged from a persistent clinical observation: many patients with schizophrenia report gastrointestinal complaints, and multiple surveys have documented altered gut microbiome compositions in affected individuals. What has been missing is a causal account of how such microbial shifts could translate into neural dysfunction. Correlation alone cannot settle whether dysbiosis is a driver of symptoms, a side effect of antipsychotic medication, or a consequence of lifestyle differences. The Coimbra team therefore designed a transplantation experiment in which gut microbiota from schizophrenia patients was introduced into wild-type BALB/cByJ mice, allowing the researchers to observe, under controlled conditions, what the microbial community alone could do to a healthy host.

The results were striking. Mice receiving the schizophrenia-derived microbiota developed ileal dysbiosis, meaning their own gut bacterial communities became disturbed in ways resembling the donor profile. This was accompanied by inflammation in the intestine and disruption of the intestinal barrier, the tightly regulated epithelial lining that normally prevents bacteria and their products from leaking into the bloodstream. Barrier breakdown is a critical event because it permits microbial molecules and immune signals to travel beyond the gut, potentially influencing distant organs including the brain. The finding establishes the gut as a plausible point of origin for systemic disturbances previously observed in schizophrenia without pinpointing a mechanism.

That mechanism began to come into focus when the researchers examined the immune systems of the recipient mice. Animals carrying the schizophrenia microbiota showed elevated circulating levels of the pro-inflammatory cytokines interleukin-17 and interferon-gamma, alongside a reduction in CD4 T cells and a decreased CD4-to-CD8 ratio. Together, these signatures point to a Th17/Th1-skewed immune profile, a pattern in which helper T cell lineages that promote inflammatory responses become disproportionately activated. Th17 cells, named for their production of interleukin-17, are known to be particularly adept at breaching epithelial barriers and communicating with the nervous system, while Th1-driven interferon-gamma signaling is a hallmark of chronic inflammatory states. The immune fingerprint induced by the transplanted microbes closely resembles inflammatory abnormalities that clinicians and researchers have repeatedly documented in subsets of schizophrenia patients.

Most provocatively, the immune disturbances did not remain confined to the periphery. The mice exhibited microglial activation in the prefrontal cortex, a brain region central to working memory, decision-making, and social behavior, all of which are impaired in schizophrenia. Microglia are the resident immune cells of the central nervous system, and when activated they release cytokines and other mediators that can perturb neuronal function and synaptic maintenance. Consistent with this, the animals showed deficits in synaptic proteins, suggesting that the inflammatory environment was eroding the molecular infrastructure of neural communication. Behavioral testing confirmed functional consequences: the mice displayed hyperactivity, impaired working memory, and reduced social interaction, a triad that overlaps with core symptom domains of the human disorder.

A crucial strength of the study is that it did not rely on the mouse model alone. The researchers conducted post-mortem analyses of brain tissue from schizophrenia patients and found that the human brains recapitulated the key findings from the animals: increased microglial activation and elevated pro-inflammatory cytokine levels in the prefrontal cortex. This convergence between an experimentally induced phenotype and human neuropathology substantially strengthens the argument that the gut-immune-brain pathway the team mapped in mice is relevant to the actual biology of the disease, rather than an artifact of the transplantation procedure or the laboratory environment.

The technical design of the work reflects careful attention to confounders that have undermined earlier microbiome studies. By using wild-type mice rather than genetically modified or germ-free animals, the researchers tested whether patient-derived microbes could perturb an intact, normal immune and nervous system, a more demanding test than showing effects in a sensitized host. Human samples were obtained with informed consent under approved ethics protocols from Coimbra University Hospital, and post-mortem brain tissue came from the Neurological Tissue Bank of the Biobanco Hospital Clínic-IDIBAPS in Barcelona. Animal procedures complied with European Union and Portuguese legislation and were overseen by institutional welfare committees, ensuring that the translational claims rest on methodologically defensible ground.

The implications for treatment are potentially far-reaching. If gut dysbiosis contributes to the immune and synaptic pathology of schizophrenia, then microbiota-targeted interventions, including dietary modification, probiotics, prebiotics, or in more speculative scenarios fecal microbiota transplantation, could offer adjunctive therapies that complement existing antipsychotic medications. Current drugs largely address positive symptoms such as hallucinations and delusions while leaving cognitive deficits and negative symptoms poorly treated. A therapeutic avenue aimed at calming intestinal inflammation and rebalancing immune signaling might, in principle, reach aspects of the illness that dopamine-targeting drugs cannot. The authors frame their findings as providing a conceptual framework for such microbiota-targeted strategies, while the data themselves stop short of demonstrating that correcting dysbiosis reverses any aspect of the disease.

Important caveats remain. The study shows that schizophrenia-associated microbiota can induce disease-relevant changes in mice, but it does not establish that gut bacteria initiate schizophrenia in humans, nor does it identify which specific microbial species or strains carry the pathogenic potential. Schizophrenia is a heterogeneous condition, and the patients whose microbiota was transplanted may have shared environmental, dietary, or medication-related factors that shaped their gut communities. Whether the observed microglial activation and synaptic protein deficits in mice arise through microbial metabolites, immune cell trafficking, or vagal nerve signaling is a question the study leaves open for future work. Longitudinal studies in patients, along with experiments identifying the responsible microbial components, will be needed to convert this mechanistic framework into clinical practice.

Nevertheless, the study marks a significant advance in a field that has often been accused of overpromising. By connecting a human-derived microbial community to specific immune signatures, defined brain-region pathology, measurable synaptic changes, and quantifiable behavioral abnormalities, and then validating the brain findings in human post-mortem tissue, the Coimbra team has assembled a coherent mechanistic chain from gut to brain. For a disorder that affects roughly one in every hundred people worldwide and remains one of the leading causes of disability, any new biological handle is welcome. The message of this research is that the brain in schizophrenia may not be sick alone; the gut, the immune system, and the resident microbes of the digestive tract appear to be part of the conversation, and learning to listen to that conversation could reshape how the illness is understood and treated.

Subject of Research: The role of the gut microbiome-immune-brain axis in the pathophysiology of schizophrenia

Article Title: Unveiling the gut microbiome-immune-brain axis in schizophrenia

Article References: Pereira-Santos, A. R., Candeias, E., Maranha, A., Esteves, A. R., Alarico, S., Tiago, I., Bajouco, M., Madeira, N., Empadinhas, N., & Cardoso, S. M. (2026). Unveiling the gut microbiome-immune-brain axis in schizophrenia. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04497-2

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04497-2

Keywords: schizophrenia, gut microbiome, gut-brain axis, microglial activation, Th17 cells, interleukin-17, interferon-gamma, prefrontal cortex, intestinal barrier, synaptic proteins, neuroinflammation, microbiota transplantation